Amolyt Pharma enters research agreement, licensing option with XOMA

Amolyt Pharma entered into a research agreement and licensing option with XOMA Corporation for the pre-clinical evaluation of a select set of monoclonal antibodies that arose from XOMA’s legacy discovery efforts as potential treatments for primary hyperparathyroidism and humoral hypercalcemia of malignancy. Amolyt has the option to license one or more of these candidates from XOMA for further clinical development worldwide. Both PHPT and HHM are rare endocrine diseases with high unmet needs and a common target, the parathyroid hormone 1 receptor, and are characterized by the hypersecretion of parathyroid hormone and parathyroid hormone-related peptide, respectively, resulting in continuous stimulation of the PTHR1, leading to bone loss, hypercalcemia and hypophosphatemia. The objective of the research agreement is to test the anti-PTHR1 antibodies in relevant animal disease models with the aim of selecting a candidate that can successfully halt the over-stimulation of the PTHR1 caused by excess PTH and PTHrP and eliminate the debilitating symptoms and serious complications associated with PHPT and HHM.